Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response

Miao Yu; Dorothea Terhorst-Molawi; Sabine Altrichter; Tomasz Hawro; Yu-Di Chen; Bo Liu; Xiao-Ting Song; Zuo-Tao Zhao; Marcus Maurer

doi:10.1111/cea.13838

Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response

Clin Exp Allergy. 2021 May;51(5):730-734. doi: 10.1111/cea.13838. Epub 2021 Feb 8.

Authors

Miao Yu^{1

2

3

4}, Dorothea Terhorst-Molawi⁵, Sabine Altrichter⁵, Tomasz Hawro⁵, Yu-Di Chen⁶, Bo Liu^{1

2

3}, Xiao-Ting Song^{1

2

3}, Zuo-Tao Zhao^{1

2

3}, Marcus Maurer⁵

Affiliations

¹ Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
² Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
³ National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
⁴ Peking University School of Nursing, Beijing, China.
⁵ Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁶ Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 33522024
DOI: 10.1111/cea.13838

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Chronic Urticaria / drug therapy*
Duration of Therapy
Female
Humans
Male
Omalizumab / therapeutic use*
Retrospective Studies
Time Factors
Treatment Outcome
Young Adult

Substances

Anti-Allergic Agents
Omalizumab